X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SGT-003 uses a proprietary, rationally designed capsid (AAV-SLB101) to deliver a DNA sequence encoding microdystrophin, containing the R16-R17 nNOS binding domain. It is evaluated in preclinical studies for duchenne muscular dystrophy.
Lead Product(s): SGT-003
Therapeutic Area: Genetic Disease Product Name: SGT-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2024
Details:
Armatus Bio for the use of Solid’s proprietary capsid AAV-SLB101 for the development and commercialization of Armatus’ vectorized RNAi candidate to treat Facioscapulohumeral muscular dystrophy.
Lead Product(s): SGT-003
Therapeutic Area: Genetic Disease Product Name: SGT-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Armatus Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 07, 2024
Details:
SGT-003 uses a proprietary, rationally designed capsid (AAV-SLB101) to deliver a DNA sequence encoding microdystrophin, containing the R16-R17 nNOS binding domain. It is evaluated in preclinical studies for duchenne muscular dystrophy.
Lead Product(s): SGT-003
Therapeutic Area: Genetic Disease Product Name: SGT-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The Company expects to use net proceeds to fund ongoing pipeline development programs, including SGT-003, a next-generation gene therapy candidate for the treatment of duchenne muscular dystrophy.
Lead Product(s): SGT-003
Therapeutic Area: Genetic Disease Product Name: SGT-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Citigroup
Deal Size: $108.9 million Upfront Cash: Undisclosed
Deal Type: Private Placement January 08, 2024
Details:
SGT-003 is a fast track designated Cell and Gene therapy drug infused intravenously and is being investigated for treating Duchenne Muscular Dystrophy, containing the microdystrophin DNA sequence.
Lead Product(s): SGT-003
Therapeutic Area: Genetic Disease Product Name: SGT-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
SGT-003 uses a proprietary, rationally designed capsid (AAV-SLB101) to deliver a DNA sequence encoding a shortened form of the dystrophin protein, which is investigated for the treatment of Duchenne Muscular Dystrophy.
Lead Product(s): SGT-003
Therapeutic Area: Genetic Disease Product Name: SGT-003
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 14, 2023
Details:
The collaboration will integrate Solid Biosciences’ vector biology, manufacturing capabilities and drug development experience with Phlox’s deep expertise in genetic cardiomyopathies and RNA therapeutics to develop novel precision genetic medicines for this form of DCM.
Lead Product(s): Genetic Medicine
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Phlox Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2023
Details:
AVB-202 is being developed with a transgene to encode full-length frataxin protein (210 amino acids) packaged into an AAV9 capsid under the control of a promoter specifically designed to drive expression in neurons and cardiac cells.
Lead Product(s): AVB-202
Therapeutic Area: Genetic Disease Product Name: AVB-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: AavantiBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 05, 2022
Details:
SGT-003 is Solid's next-generation AAV gene transfer therapy candidate that utilizes a rationally designed, novel muscle-tropic AAV capsid, called AAV-SLB101, to deliver Solid’s proprietary and differentiated nNOS microdystrophin for the treatment of Duchenne.
Lead Product(s): AAV-SLB101
Therapeutic Area: Genetic Disease Product Name: SGT-003
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 17, 2022
Details:
AVB-202 is being developed with a transgene to encode full-length frataxin protein (210 amino acids) packaged into an AAV9 capsid under the control of a promoter specifically designed to drive expression in neurons and cardiac cells.
Lead Product(s): AVB-202
Therapeutic Area: Genetic Disease Product Name: AVB-202
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: AavantiBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
